
Clinical trial enrollment nerd. SVP, Analytics, Insights, & Media at @Continuumclinic. Slowing rolling off to @Ivsin@med-mastodon.com
Chicago, IL, USA
Joined October 2009
- Tweets1.5K
- Following1.8K
- Followers1.2K
- Likes976
Paul Ivsin retweeted
As you might have heard, the recent fine handed down to Meta for GDPR violations is getting a lot of attention and raising a lot of questions. We dug into the ruling to better understand it and the impact it might have on #ClinicalTrials.
continuumclinical.com/news/h…
Paul Ivsin retweeted
We are proud to celebrate #ClinicalTrialsDay, which serves as a reminder for all of us that we are working to advance medical research for all. In this video, we talk about why we are passionate about what we do.
@ACRPDC #CTD2023
youtu.be/p6WvvnW88Ro
"World record".
I do hope a Guinness rep was on hand to certify that.
Bryan Johnson sold his company to PayPal for $800 million in 2013.
Since then, he's been investing millions to reduce aging.
In 2021, he reduced his epigenetic age by 5.1 years in 7 months (World Record)
Here’s a breakdown of his “Blueprint” and my own experience with it: 🧵
Paul Ivsin retweeted
Since it's #InternationalMensDay, here's a thread of every part of the gynaecological anatomy that is named after a man, with a bit of trivia about each man. Some of the bits are very specific. Before you ask, there are no parts of the gynaecological anatomy named after women...
Paul Ivsin retweeted
10 women statisticians and data scientists who helped us understand Covid-19
ow.ly/Sofc50L6G4j
Paul Ivsin retweeted
Our RCT of e-mail alerts to reduce risky opioid prescribing is out today in @JAMAHealthForum. We tested e-mails from pharmacists to prescribers & primary care managers to cut opioid interactions.
Result: no detected impacts on Rx.
Read on for more!
jamanetwork.com/journals/jam…
Paul Ivsin retweeted
Great e.g of how causal inference fails in obs non-random comparisons. Here-- CABG vs PCI.
Classic signal of confounding is early separation of curves. CABG may be better than PCI, but not in the first 6 mo-12 mo
Early sep means healthier pts had Surg
h't @rwyeh
Coronary artery bypass w/ multiarterial grafting versus percutaneous: superior outcomes w/CABG vs PCI!!
@VictorDayan1 @pomyers @rafasadaba @EduQuintanaCVS @FaisalBakaeen @djc795 @pash22 @ajaykirtane @rojasfec @rwyeh @torresviera @Hragy @dompagano @essadii sciencedirect.com/science/ar…
Paul Ivsin retweeted
OK, quick story (with props to @quoteresearch for doing the work.)
In 1977, Newsweek published an cover story called "Seeking Other Worlds" which, in part, profiled Carl Sagan. This article ended with a quote from Carl:
Get good at math and mathematical reasoning, learn to think (self-) critically to become a Data Analyst. The tools are the least important part, and can be picked up later. The tools will never substitute for thought.
Paul Ivsin retweeted
FDA needs to get out of the booster-promoting business to focus on their mission to evaluate data. CDC is there to promote what they recommend. I can't handle FDA promoting drugs. They'e crossing a line. They're traditional role is informed consent & critical review of the data.
I have tried to explain to my bus driver that the proper endpoint of the bus route should be my house. In fact, in a survey of my fellow riders, "my house" was the most-selected option for endpoints. And yet, arrogantly, the driver continues to run the bus down the main street.
Do trialists and patients and health professionals choose the same trial primary outcomes?
For breast cancer and nephrology it's No. What's more, it's no most of the time.
A new @Trial_Forge study out today trialsjournal.biomedcentral.…
1
2
Paul Ivsin retweeted
Our new study shows that data availability statements are not very useful; 1670 (93%) authors who indicated that data are available on request either did not respond or declined to share their data with us. Journal of Clinical Epidemiology: doi.org/10.1016/j.jclinepi.2…
Not sure about Europe, but this is not how pharma patents really work in the US, since Hatch-Waxman extensions would likely equalize the difference and greatly reduce incentive for speed.
Big Pharma will need to tool up in the data arms race in 2022, writes @aimeedonnellan reut.rs/3FqpfE0 #BVPredicts
1
Paul Ivsin retweeted
I think @ashtroid22 is getting a little some misguided 'splaining on her initial tweet, so starting a new thread here, but something that came out of it - nice 2-tweet sequence from @avicenna that captures why I tend to think ITT estimates are most important in most trials.
Paul Ivsin retweeted
Seems a misled help for extrapolation to future patients, based on the still common confusion of trials with surveys and overinterpretation of subgroup results. Nothing about, say, plausible effect moderators on specific contrast scales or power for subgroup/interaction analyses.
Here's a good idea from @NEJM: a supplementary table providing background information on the disease, problem, or condition and the representativeness of the study group. Mandatory from 1st Jan 2022. nejm.org/doi/full/10.1056/NE…
Paul Ivsin retweeted
Team it's time to address the Hoeg et al preprint on post-COVID vaccine myocarditis. How am I qualified to speak about myocarditis? I am board certified in paediatric cardiology and currently have patients recovering from this condition. TLDR: They are doing quite well. #MRI
Paul Ivsin retweeted
I am so disappointed by the large number of pre-pandemic medical skeptics have now turned into mask/vaccine skeptics. I largely agreed with many of them back in the day. /1
Paul Ivsin retweeted
I see men telling women to report sexual harassment at work to a trusted senior. I see women saying no man has ever raised their head above the parapet to challenge sexism at work.
We don’t know who our trusted seniors are unless you make yourselves known by your actions.
Paul Ivsin retweeted
A few months ago, I had some questions & concerns about exciting results published in the @ObesitySociety journal describing a trial of a personalized phenotype-guided treatment. Today, they published a correction and clarification: onlinelibrary.wiley.com/doi/…


































